# Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

*PRI Rank #3 · Topics and Trends in Most Cited Pancreatic function and diabetes Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/pancreatic-function-and-diabetes/2026/rank-3*

| Field | Value |
| --- | --- |
| Rank | #3 |
| 18m citations | 121 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-024-03133-0 |
| Corresponding authors | Johannes F.E. Mann |
| Institution | KfH Kidney Centre, Germany |

**Ranking page:** [Topics and Trends in Most Cited Pancreatic function and diabetes Papers, Class of 2026](https://pri.pepkio.com/top-papers/pancreatic-function-and-diabetes/2026)

**Paper link:** [10.1038/s41591-024-03133-0](https://doi.org/10.1038/s41591-024-03133-0)

## Topics

semaglutide · SGLT2 inhibitors · Type 2 diabetes · chronic kidney disease · FLOW trial · GLP-1 receptor agonists · kidney failure · Estimated glomerular filtration rate · cardiovascular death · Cardiovascular events · All-cause mortality · combination therapy · kidney outcomes · eGFR slope · Hazard ratio

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Pancreatic function and diabetes Papers, Class of 2026. https://pri.pepkio.com/top-papers/pancreatic-function-and-diabetes/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```